Cargando…

Traceability of Biologics in The Netherlands: An Analysis of Information-Recording Systems in Clinical Practice and Spontaneous ADR Reports

INTRODUCTION AND OBJECTIVE: Pharmacovigilance requirements for biologics mandate that EU Member States shall ensure that any biologic that is the subject of a suspected adverse drug reaction (ADR) is identifiable by brand name and batch number. Recent studies showed that brand name identification is...

Descripción completa

Detalles Bibliográficos
Autores principales: Klein, Kevin, Scholl, Joep H. G., Vermeer, Niels S., Broekmans, André W., Van Puijenbroek, Eugène P., De Bruin, Marie L., Stolk, Pieter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4735237/
https://www.ncbi.nlm.nih.gov/pubmed/26719190
http://dx.doi.org/10.1007/s40264-015-0383-8
_version_ 1782413044393967616
author Klein, Kevin
Scholl, Joep H. G.
Vermeer, Niels S.
Broekmans, André W.
Van Puijenbroek, Eugène P.
De Bruin, Marie L.
Stolk, Pieter
author_facet Klein, Kevin
Scholl, Joep H. G.
Vermeer, Niels S.
Broekmans, André W.
Van Puijenbroek, Eugène P.
De Bruin, Marie L.
Stolk, Pieter
author_sort Klein, Kevin
collection PubMed
description INTRODUCTION AND OBJECTIVE: Pharmacovigilance requirements for biologics mandate that EU Member States shall ensure that any biologic that is the subject of a suspected adverse drug reaction (ADR) is identifiable by brand name and batch number. Recent studies showed that brand name identification is well established, whereas batch numbers are (still) poorly reported. We evaluated information-recording systems and practices in the Dutch hospital setting to identify determinants for brand name and batch number recording as well as success factors and bottlenecks for traceability. METHODS: We surveyed Dutch hospital pharmacists with an online questionnaire on systems and practices in hospitals for recording brand names and batch numbers. Additionally, we performed an analysis of the traceability of recombinant biologics in spontaneous ADR reports (received between 2009 and 2014) from the Netherlands Pharmacovigilance Centre Lareb. RESULTS: The survey showed that brand names are not routinely recorded in the clinical practice of Dutch hospitals, whereas batch numbers are poorly recorded. Seventy-six percent of the 1523 ADR reports for recombinant biologics had a traceable brand name whereas 5 % of these reports contained a batch number. The results suggest a possible relationship between the availability of brand and batch number information in clinical practice and the inclusion of this information in ADR reports for biologics. CONCLUSION: The limited traceability of brand names and batch numbers in ADR reports may be primarily caused by the shortcomings in the recording of information in clinical practice. We recommend efforts to improve information-recording systems as a first step to improve the traceability of biologics in ADR reporting. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s40264-015-0383-8) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4735237
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-47352372016-02-09 Traceability of Biologics in The Netherlands: An Analysis of Information-Recording Systems in Clinical Practice and Spontaneous ADR Reports Klein, Kevin Scholl, Joep H. G. Vermeer, Niels S. Broekmans, André W. Van Puijenbroek, Eugène P. De Bruin, Marie L. Stolk, Pieter Drug Saf Original Research Article INTRODUCTION AND OBJECTIVE: Pharmacovigilance requirements for biologics mandate that EU Member States shall ensure that any biologic that is the subject of a suspected adverse drug reaction (ADR) is identifiable by brand name and batch number. Recent studies showed that brand name identification is well established, whereas batch numbers are (still) poorly reported. We evaluated information-recording systems and practices in the Dutch hospital setting to identify determinants for brand name and batch number recording as well as success factors and bottlenecks for traceability. METHODS: We surveyed Dutch hospital pharmacists with an online questionnaire on systems and practices in hospitals for recording brand names and batch numbers. Additionally, we performed an analysis of the traceability of recombinant biologics in spontaneous ADR reports (received between 2009 and 2014) from the Netherlands Pharmacovigilance Centre Lareb. RESULTS: The survey showed that brand names are not routinely recorded in the clinical practice of Dutch hospitals, whereas batch numbers are poorly recorded. Seventy-six percent of the 1523 ADR reports for recombinant biologics had a traceable brand name whereas 5 % of these reports contained a batch number. The results suggest a possible relationship between the availability of brand and batch number information in clinical practice and the inclusion of this information in ADR reports for biologics. CONCLUSION: The limited traceability of brand names and batch numbers in ADR reports may be primarily caused by the shortcomings in the recording of information in clinical practice. We recommend efforts to improve information-recording systems as a first step to improve the traceability of biologics in ADR reporting. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s40264-015-0383-8) contains supplementary material, which is available to authorized users. Springer International Publishing 2015-12-30 2016 /pmc/articles/PMC4735237/ /pubmed/26719190 http://dx.doi.org/10.1007/s40264-015-0383-8 Text en © The Author(s) 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Research Article
Klein, Kevin
Scholl, Joep H. G.
Vermeer, Niels S.
Broekmans, André W.
Van Puijenbroek, Eugène P.
De Bruin, Marie L.
Stolk, Pieter
Traceability of Biologics in The Netherlands: An Analysis of Information-Recording Systems in Clinical Practice and Spontaneous ADR Reports
title Traceability of Biologics in The Netherlands: An Analysis of Information-Recording Systems in Clinical Practice and Spontaneous ADR Reports
title_full Traceability of Biologics in The Netherlands: An Analysis of Information-Recording Systems in Clinical Practice and Spontaneous ADR Reports
title_fullStr Traceability of Biologics in The Netherlands: An Analysis of Information-Recording Systems in Clinical Practice and Spontaneous ADR Reports
title_full_unstemmed Traceability of Biologics in The Netherlands: An Analysis of Information-Recording Systems in Clinical Practice and Spontaneous ADR Reports
title_short Traceability of Biologics in The Netherlands: An Analysis of Information-Recording Systems in Clinical Practice and Spontaneous ADR Reports
title_sort traceability of biologics in the netherlands: an analysis of information-recording systems in clinical practice and spontaneous adr reports
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4735237/
https://www.ncbi.nlm.nih.gov/pubmed/26719190
http://dx.doi.org/10.1007/s40264-015-0383-8
work_keys_str_mv AT kleinkevin traceabilityofbiologicsinthenetherlandsananalysisofinformationrecordingsystemsinclinicalpracticeandspontaneousadrreports
AT scholljoephg traceabilityofbiologicsinthenetherlandsananalysisofinformationrecordingsystemsinclinicalpracticeandspontaneousadrreports
AT vermeernielss traceabilityofbiologicsinthenetherlandsananalysisofinformationrecordingsystemsinclinicalpracticeandspontaneousadrreports
AT broekmansandrew traceabilityofbiologicsinthenetherlandsananalysisofinformationrecordingsystemsinclinicalpracticeandspontaneousadrreports
AT vanpuijenbroekeugenep traceabilityofbiologicsinthenetherlandsananalysisofinformationrecordingsystemsinclinicalpracticeandspontaneousadrreports
AT debruinmariel traceabilityofbiologicsinthenetherlandsananalysisofinformationrecordingsystemsinclinicalpracticeandspontaneousadrreports
AT stolkpieter traceabilityofbiologicsinthenetherlandsananalysisofinformationrecordingsystemsinclinicalpracticeandspontaneousadrreports